How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/haemophilus-influenzae-pharyngitis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Haemophilus Influenzae Pharyngitis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Haemophilus Influenzae Pharyngitis (disease) competitive landscape: 6 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

6 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Haemophilus Influenzae Pharyngitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Amoxil	amoxicillin	Generic (originally Beecham/GSK)	Aminopenicillin (Beta-lactam antibiotic)	5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C	1972-01-01
Unasyn	AMPICILLIN	Bristol-Myers Squibb	Penicillin-class Antibacterial	Transient receptor potential cation channel subfamily M member 4	1965-01-01
Demethylchlortetracycline	DEMECLOCYCLINE	Pfizer	Tetracycline-class Antimicrobial	Estrogen receptor beta	1960-01-01
Amoxycillin	Amoxycillin	King George's Medical University		5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C
Meclan	MECLOCYCLINE	Johnson And Johnson	meclocycline
Amoxicilli	Amoxicilli	Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.		5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Bristol-Myers Squibb · 1 drug in Haemophilus Influenzae Pharyngitis
Generic (originally Beecham/GSK) · 1 drug in Haemophilus Influenzae Pharyngitis
Johnson And Johnson · 1 drug in Haemophilus Influenzae Pharyngitis
King George's Medical University · 1 drug in Haemophilus Influenzae Pharyngitis
Pfizer · 1 drug in Haemophilus Influenzae Pharyngitis
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. · 1 drug in Haemophilus Influenzae Pharyngitis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Haemophilus Influenzae Pharyngitis:

Cite this brief

Drug Landscape (2026). Haemophilus Influenzae Pharyngitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/haemophilus-influenzae-pharyngitis. Accessed 2026-06-10.

Haemophilus Influenzae Pharyngitis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing